Artesunate improves venetoclax plus cytarabine aml cell targeting by regulating the noxa/bim/mcl-1/p-chk1 axis

HIGHLIGHTS

• who: Jingyi Zhang from the These experiments were conducted in accordance with the requirements of animal experiment ethics committee of Shenyang Pharmaceutical UniversityNOD/SCID mice (, weeks, Beijing Weitonglihua) were injected with , u00d7 , log-phase , cells subcutaneously in the right flank [45]. Mice with tumors of about , mm, were randomized to eight groups of five mice each and were treated with artesunate (, mg/kg, i.p.), venetoclax (, mg/kg, p.o.), or cytarabine (, mg/kg, i.p.) alone or in combination for , days. Artesunate was dissolved in, % (5% NaHCO3) +, % saline, venetoclax in, % ethanol +, % PEG +, % Phosal , PG, and cytarabine . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.